Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Purpose: To evaluate the long-term impact of COVID-19 on kidney function in kidney transplant recipients who survived the infection, comparing outcomes before and after the vaccination era.
This retrospective cohort study including KTRs consisted of two distinct analysis. In the first, we included KTRs diagnosed with COVID-19 between Mar/2020 to Aug/2022 (n=4,123), comparing early (AKI, RRT requirement and death) and late (2-yr acute rejection, graft loss, and death) outcomes between the pre- and post-vaccination (and Omicron predominance). In the second, we included only survivor patients who achieved 3 months after infection with a functional graft, focusing on 2 years estimated graft function (eGFR using CKD-EPI 2021, ml/min/1.73m2) slope using a linear model by generalized estimating equation. This included a control group of KTRs transplanted between 2014-2016 and followed until 2019 (before the pandemic; n=2,481), compared with those diagnosed with COVID-19 within 3 years post-transplantation (n=455).
In the first analysis, the vaccination significantly reduced the rates of AKI (from 36.2% to 14.6%, p<0.001), RRT requirement (from 17.2% to 5.3%, p<0.001), and death (from 28.1% to 8.9% p<0.001). Next, 3,227 patients were included in the for late outcomes analysis. 2-yr acute rejection (1.5% vs. 1.5%, p=0.86), patient (4.5% vs. 4.2%, p=0.73) and global graft survival (9.3% vs. 8.1%, p=0.21) were similar in both eras. In the second analysis, the eGFR slope was stratified according to the donor type and compared with a historic control group followed before the pandemic. Among deceased donor KTRs, the two-year negative eGFR slope worsened from -3.29 (-3.93 to -2.66) in the pre-COVID era to -7.66 (-9.66 to -5.66) in the post-COVID era (p<0.001). Similarly, among living donor KTRs, the slope declined from -3.62 (-4.69 to -2.56) to -9.25 (-12.6 to -5.86) (p<0.001). Interestingly, the magnitude of the negative slope was not influenced by vaccination (p-interaction time-vaccination= 0.93, adjusted by Bonferroni).
COVID-19 significantly accelerated eGFR decline in KTRs. While widespread vaccination markedly reduced the rates of AKI and mortality, it did not prevent the accelerated decline in graft function in those who survived the infection.
